Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot
CPT®
90630

CPT® Code 90630
Deleted

Official Description

Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 90630 refers to a specific type of influenza virus vaccine known as the quadrivalent, split virus, preservative-free formulation intended for intradermal use. This vaccine is designed to provide active, long-term immunity against influenza by introducing altered versions of the virus into the recipient's immune system. Unlike immune globulins, which offer short-term, passive immunity, vaccines stimulate the body to produce its own antibodies, enabling it to recognize and combat the virus upon future exposure. The term "preservative-free" indicates that this vaccine does not contain the preservative thimerosal, or contains only trace amounts, and is classified as either thimerosal-free or thimerosal-reduced by the FDA. The administration of this vaccine occurs via intradermal injection, a method that allows for the vaccine to be delivered into the skin rather than into the muscle. The production of this influenza vaccine involves the use of embryonated chicken eggs, where the virus is cultivated, harvested, and inactivated using formaldehyde. The process includes concentrating and purifying the virus, followed by chemical disruption to create a split virus, which is then further purified. The quadrivalent formulation is specifically designed to protect against four distinct influenza viruses, comprising two strains of influenza type A and two strains of influenza type B, thereby enhancing the vaccine's effectiveness in providing comprehensive protection against circulating influenza strains.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The influenza virus vaccine, quadrivalent (CPT® Code 90630), is indicated for the prevention of influenza disease caused by the circulating strains of the virus. The vaccine is particularly recommended for individuals who are at higher risk of developing complications from influenza, including:

  • High-Risk Populations Individuals such as the elderly, young children, pregnant women, and those with chronic health conditions (e.g., asthma, diabetes, heart disease) who may experience severe illness from influenza.
  • Healthcare Workers Professionals who are in close contact with patients and are at increased risk of exposure to the influenza virus.
  • Travelers Individuals traveling to areas where influenza is prevalent, especially during flu season.

2. Procedure

The administration of the quadrivalent influenza virus vaccine involves several key procedural steps, which are as follows:

  • Step 1: Preparation Prior to administration, the vaccine must be prepared according to the manufacturer's guidelines. This includes ensuring that the vaccine is at the appropriate temperature and that the vial is inspected for any abnormalities.
  • Step 2: Patient Assessment The healthcare provider should conduct a brief assessment of the patient to confirm eligibility for vaccination, including reviewing any contraindications or previous allergic reactions to vaccines.
  • Step 3: Site Selection The intradermal injection site is typically chosen on the forearm, where the skin is relatively thin and easily accessible. The area should be cleaned with an alcohol swab to minimize the risk of infection.
  • Step 4: Injection Technique Using a fine-gauge needle, the vaccine is injected into the dermal layer of the skin. The provider should ensure that the needle is inserted at the correct angle to achieve intradermal delivery.
  • Step 5: Post-Administration Care After the injection, the site may be covered with a bandage if necessary. The patient should be monitored for a brief period to observe for any immediate adverse reactions.

3. Post-Procedure

Following the administration of the quadrivalent influenza virus vaccine, patients are typically advised to remain in the healthcare setting for a short period to monitor for any immediate allergic reactions, such as anaphylaxis. Common post-vaccination reactions may include mild soreness at the injection site, low-grade fever, or fatigue, which usually resolve within a few days. Patients should be informed about the importance of reporting any unusual or severe reactions to their healthcare provider. Additionally, it is recommended that individuals continue to practice preventive measures against influenza, such as hand hygiene and avoiding close contact with sick individuals, even after vaccination.
Short Descr FLU VACC IIV4 NO PRESERV ID
Medium Descr INFLUENZA VACC IIV4 SPLIT VIRUS PRSRV FREE ID
Long Descr Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use
Related Drugs FLUZONE INTRADERMAL QUADRIVALENT
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
APC Status Indicator Influenza, Pneumococcal Pneumonia, Hepatitis B, and Covid-19 Vaccines; Monoclonal Antibody Therapy Product
Type of Service (TOS) 1 - Medical Care
Berenson-Eggers TOS (BETOS) O1G - Immunizations/Vaccinations
MUE Not applicable/unspecified.
95 Synchronous telemedicine service rendered via a real-time interactive audio and video telecommunications system: synchronous telemedicine service is defined as a real-time interaction between a physician or other qualified health care professional and a patient who is located at a distant site from the physician or other qualified health care professional. the totality of the communication of information exchanged between the physician or other qualified health care professional and the patient during the course of the synchronous telemedicine service must be of an amount and nature that would be sufficient to meet the key components and/or requirements of the same service when rendered via a face-to-face interaction. modifier 95 may only be appended to the services listed in appendix p. appendix p is the list of cpt codes for services that are typically performed face-to-face, but may be rendered via a real-time (synchronous) interactive audio and video telecommunications system.
GW Service not related to the hospice patient's terminal condition
Date
Action
Notes
2024-12-31 Deleted Code Deleted. See 90653, 90655, 90656, 90657, 90658, 90660, 90661, 90662, 90664, 90666, 90667, 90668, 90672, 90673, 90674, 90682, 90685, 90686, 90687, 90688, 90689, 90694, 90756
2015-01-01 Added Added. FDA approval was granted on December 11, 2014.
1991-12-31 Deleted Code deleted.
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"